Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 189, Issue 1, 2003, Pages 28-36

  Möbus, Volker J ^a   Baum, Richard P ^b   Bolle, Marcus ^c   Kreienberg, Rolf ^c   Noujaim, Antoine A ^d   Schultes, Birgit C ^e   Nicodemus, Christopher F ^e  

^a Eye Hospital   (Germany)

^b Zentralklinik ^*  (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d AltaRex Corp   (Canada)

^e AltaRex US Corp   (United States)

Author keywords

Monoclonal antibody B43.13; Ovarian cancer; Vaccine

Indexed keywords

CA 125 ANTIGEN; OREGOVOMAB; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SURVIVAL RATE;

EID: 0038336598     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.347     Document Type: Article

References (23)

1. Fernandez N, Duffour MT, Perricaudet M, Lotze MT, Tursz T, Zitvogel L. Active specific T-cell based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines: principles and future prospects. Cytokines Cell Mol Ther 1998;4:53-65.
2. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998;19:89-97.
3. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974;125:373-89.
4. Chatterjee M, Foon K, Köhler H. Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother 1994;38:75-82.
5. Jefferis R. What is an idiotype? Immunol Today 1993;14:119-21.
6. Sykes TR, Woo TK, Baum RP, Noujaim AA. Direct labeling of monoclonal antibodies with technetium-99m by photoactivation. J Nucl Med 1995;36:1913-22.
7. Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with OvaRex MAb B43.14 (Ab1). Cancer Immunol Immunother 1998;46:201-12.
8. Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13: evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm 2001;16:187-203.
9. Bookman M, Rettenmaier M, Gordon A, Tuccillo D, Fingert H. Monoclonal antibody (oregovomab) targeting of CA125 in patients (pts) with advanced epithelial ovarian cancer (EOC) and elevated CA125 after response to initial therapy [abstract]. Clin Cancer Res 2001;7(Suppl):3756s.
10. Berek J, Ehlen T, Gordon A, Nicodemus C, Schultes B, Whiteside T, et al. Interim analysis of a double blind study of OvaRex® MAb-B43.13 versus placebo in patients with ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2001;2:210a.
11. Hu SL, Hellstrom I, Hellstrom KE. Recent advances in antitumor vaccines. Biotechnology 1992;20:327-43.
12. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hör G, et al. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 1995;14:199-203.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley; 1980.
15. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
16. Vasey P, on behalf of the Scottish Gynaecologic Cancer Trials Group. Preliminary results of the SCOTROC Trial: a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC) [abstract]. Proc Am Soc Clin Oncol 2001;20:202a.
17. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
18. Ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
19. Ehlen T, Whiteside T, Schultes BC, Siemens M, Noujaim AA, Nicodemus CF. Induction of tumor protective immunity utilizing the CA125 specific monoclonal, OvaRex® MAb-B43.13 in a cohort of patients with advanced recurrent ovarian cancer. Gynecol Oncol 2001;80:310-6.
20. Schultes BS, Agopsowicz K, Kuzma M, Nicodemus C, Noujaim A, Mann D. Antibody-antigen immune complexes allow for efficient MHC class 1 and 1I-restricted antigen presentation and maturation of dendritic cells: a novel strategy for cancer immunotherapy [abstract]. Proc Am Assoc Cancer Res 2001;42:276.
21. Bolle M, Niesen A, Korz W, Nicodemus C, Conlon K, Noujaim A, et al. Possible role of anti-CA125 monoclonal antibody B43.13 (OvaRex) administration in long-term survival of relapsed ovarian cancer patients [abstract]. Proc Am Soc Clin Oncol 2000;19:476a.
22. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, et al. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 1993;12:583-9.
23. Wagner U, Köhler S, Reinartz S, Giffels P, Huober J, Renke K, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001;7:1154-62.